Avinger, Inc (AVGR)

Etorro trading 970x250
Avinger, Inc (AVGR) Logo

About Avinger, Inc

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California. Address: 400 Chesapeake Drive, Redwood City, CA, United States, 94063

Avinger, Inc News and around…

Latest news about Avinger, Inc (AVGR) common stock and company :

Avinger: Q2 Earnings Insights
11 Aug, 2022 FinancialContent

Avinger (NASDAQ:AVGR) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:01 PM. Here's what investors ...

Avinger Reports Second Quarter 2022 Results
11 Aug, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / August 11, 2022 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2022.

Avinger, Inc. Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-the-Market Under Nasdaq Rules
08 Aug, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / August 8, 2022 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the closing of its previously announced registered direct and private placement offerings priced at-the-market under Nasdaq rules, including the issuance and sale of (i) 700,000 shares of common stock and 784,019 pre-funded warrants in the registered direct offering and (ii) 1,369,864 pre-funded warrants in the private placement. The gross proceeds to Avinger from the offerings are approximately $5 million, before deducting placement agent fees and other offering expenses.

Avinger to Announce Second Quarter 2022 Results on August 11
05 Aug, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2022 after the close of trading on Thursday, August 11, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
04 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca/Merck's ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
04 Aug, 2022 FinancialContent

Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) stock increased by 109.5% to $9.26 during Thursday's pre-market ...

Avinger Announces $5 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
04 Aug, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / August 4, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the sale and issuance of 1,484,019 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,369,864 shares of common stock (or pre-funded warrants in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. The purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and the associated preferred investment options is $1.752.

Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
21 Jul, 2022 FinancialContent

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is ...

Avinger Announces Filing of 510(k) Submission for Tigereye ST Image-Guided CTO Crossing System
06 Jul, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / July 6, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for the Tigereye ST catheter, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform.

Avinger Expands International Presence with First Commercial Shipment to Chile
21 Jun, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / June 21, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the expansion of its international presence with the commercial launch of its Lumivascular products in Chile. Avinger's new Lightbox 3 imaging console will be used exclusively to support the launch of the Lumivascular platform in Chile.

Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC 2022
15 Jun, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / June 15, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations and a live case transmission featuring the company's Lumivascular technology at the Leipzig Interventional Course (LINC) 2022, which took place June 6 through June 9. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germany.

Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
06 Jun, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / June 6, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place May 31 through June 3 in New Orleans.

12 Health Care Stocks Moving In Friday's Pre-Market Session
27 May, 2022 FinancialContent

Gainers Avadel Pharmaceuticals (NASDAQ:AVDL) stock increased by 32.7% to $1.42 during Friday's pre-market session. ...

Avinger Announces Key Opinion Leader Presentation and Live Case at Vascular Conferences in Germany
16 May, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / May 16, 2022 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced a key opinion leader (KOL) presentation and a live-case event featuring the Company's Lumivascular technology at two important vascular conferences in Germany: the annual CLI Congress on May 6-7 and Masterclass Münster on May 9-10.

99 Biggest Movers From Yesterday
12 May, 2022 FinancialContent

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus ...

52 Stocks Moving In Wednesday's Mid-Day Session
11 May, 2022 FinancialContent

Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of ...

Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates
10 May, 2022 Yahoo! Finance

Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Recap: Avinger Q1 Earnings
10 May, 2022 FinancialContent

Avinger (NASDAQ:AVGR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:01 PM. Here's what investors need to know about ...

Avinger Reports First Quarter 2022 Results
10 May, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / May 10, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2022.

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer ...

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
04 May, 2022 Yahoo! Finance

AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

12 Health Care Stocks Moving In Wednesday's After-Market Session
04 May, 2022 FinancialContent

Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market ...

Avinger to Announce First Quarter 2022 Results on May 10
29 Apr, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / April 29, 2022 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2022 after the close of trading on Tuesday, May 10, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

12 Health Care Stocks Moving In Monday's After-Market Session
25 Apr, 2022 FinancialContent

Gainers Avadel Pharmaceuticals (NASDAQ:AVDL) stock moved upwards by 30.6% to $5.5 during Monday's after-market session. This security ...

Avinger Announces Full Commercial Launch of Lightbox 3
19 Apr, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / April 19, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial availability of its new Lightbox 3 imaging console designed to enhance the user experience and drive faster adoption at new hospital sites.

Avinger Announces Issuance of Three New U.S. Patents in March 2022
30 Mar, 2022 FinancialContent

16 New U.S. and International Patents Issued over Past Year

Avinger Regains Compliance with Nasdaq Listing Requirements
29 Mar, 2022 FinancialContent

REDWOOD CITY, CA / ACCESSWIRE / March 29, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.

Avinger's Return On Capital Employed Overview
23 Mar, 2022 FinancialContent

Benzinga Pro data, Avinger (NASDAQ:AVGR) reported Q4 sales of $2.40 million. Earnings fell to a loss of $5.00 million, resulting in a ...

Avinger: Q4 Earnings Insights
23 Mar, 2022 FinancialContent

Avinger (NASDAQ:AVGR) reported its Q4 earnings results on Tuesday, March 22, 2022 at 04:01 PM. Here's what investors ...

Avinger (AVGR) Reports Q4 Loss, Tops Revenue Estimates
22 Mar, 2022 Yahoo! Finance

Avinger (AVGR) delivered earnings and revenue surprises of 0% and 4.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avinger, Inc (AVGR) is a NASDAQ Common Stock listed in , ,

970x250